Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
litifilimab
- Development stage
- Phase 3
- Lead developer
- Biogen
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
Litifilimab is a humanized IgG1 monoclonal antibody that targets blood dendritic cell antigen 2 (BDCA2), a receptor exclusively expressed on plasmacytoid dendritic cells (pDCs)[5][7]. By binding to BDCA2, litifilimab inhibits the activity of pDCs and reduces the production of type I interferons and other proinflammatory cytokines and chemokines[1][5][6]. These mediators are implicated in the pathogenesis of autoimmune diseases such as systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE)[3][5]. Litifilimab has demonstrated efficacy in phase II clinical trials for both SLE and CLE by reducing skin disease activity and joint involvement[3][5]. The drug was discovered and developed by Biogen.
- Other names
- litifilimabBIIB059BIIB-059BIIB 05924F4AAnti-BDCA2 antibodyAnti-BDCA-2 antibodyAnti-BDCA 2 antibody
02
Targets
CLEC4C (C-type lectin domain family 4 member C)
Beyond the preview
Go deeper on litifilimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on litifilimab.